NovoMix 30

Insulin aspart 30%, protamine-crystallised insulin aspart 70%

Insulin requiring DM.

SC Individualized dosage. Type 2 DM Can be given as monotherapy or in combination w/ oral antidiabetics. Initially 6 U at breakfast & 6 U at dinner (evening meal), or 12 U at dinner. When transferring from biphasic human insulin, start w/ the same dose, then titrate as needed. Close glucose monitoring is recommended. It is generally recommended to move to bd when reaching 30 U by splitting the dose into equal breakfast & dinner doses. The morning dose can also be split in the morning & lunchtime doses (tds dosing). Dose adjustment: Adjust based on the lowest pre-meal blood glucose level from the 3 previous days. Childn ≥10 yr Can be used when premixed insulin is preferred.

Should be taken with food: Administer immediately before or soon after a meal.

Hypersensitivity.

Adjustment of dosage may be necessary if patients undertake increased physical activity, changed usual diet or during concomitant illness. Must not be administered IV. IM administration should also be avoided. Not for use in insulin infusion pumps. Seek physician's advice before travelling to different time zones. Inadequate dosing or discontinuation of treatment especially in type 1 diabetes, may lead to hyperglycaemia & diabetic ketoacidosis. Omission of a meal or unplanned strenuous physical exercise may lead to hypoglycaemia. Intensified insulin therapy, may change usual warning symptoms of hypoglycaemia. Tighter control of glucose levels can increase potential for hypoglycaemic episodes. Consider rapid onset of action patients w/ concomitant diseases or medication where a delayed absorption of food might be expected. Concomitant illness, especially infections & feverish conditions, usually increases the patients' insulin requirements. Concomitant diseases of the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in the insulin dose. Transferring to another type or brand of insulin should be done under strict medical supervision. Inj site reactions. Rotate inj site continuously. May cause formation of insulin antibodies. May impair the ability to drive & operate machinery. Pregnancy & lactation. Childn 6-9 yr.

Hypoglycaemia. Urticaria, rash, eruptions & anaphylactic reactions; refraction disorders; diabetic retinopathy; lipodystrophy; inj site reactions; oedema.

Cases of CHF may develop in combination w/ thiazolidinediones, especially in patients w/ risk factors for development of CHF. Oral antidiabetic products, MAOIs, β-blockers, ACE-inhibitors, salicylates, anabolic steroids & sulfonamides may reduce insulin requirement. OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone & danazol may increase insulin requirements. Octreotide or lanreotide may either increase or decrease the insulin requirement. β-blockers may mask hypoglycemic symptoms. Alcohol may intensify or reduce the hypoglycaemic effect.

Insulin Preparations

A10AD05 - insulin aspart ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.

POM